Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.
Department of Radiology, German Armed Forces Hospital of Ulm, Ulm, Germany.
Cell Death Dis. 2018 Jan 25;9(2):116. doi: 10.1038/s41419-017-0062-z.
Any therapy that aims at eradicating a cancerous growth will have at its core a cell death-inducing component. Here we argue that paediatric oncology presents with its unique set of considerations and problems, which-while taking the lead from oncological research experiences obtained from the adult population-need to be clinically evaluated independently. This is particularly true when considering long-term side effects. Precision medicine offers a promising new approach in therapy, but given as a monotherapy and in a limited combination, as found in an apoptosis inducer/sensitiser combination, it will most likely lead to mutation escape of the target cell population and the emergence of resistance. However, using the increasing amount of the molecular data as the basis for a complex combination therapy combining several key components such as cell death-inducing agents, kinase inhibitors and BH3 mimetics, holds great promise.
任何旨在根除癌性生长的治疗都将以诱导细胞死亡的成分为核心。在这里，我们认为儿科肿瘤学具有其独特的考虑因素和问题，这些因素需要在临床中独立评估，尽管可以借鉴从成人肿瘤研究中获得的经验。在考虑长期副作用时尤其如此。精准医学为治疗提供了一种很有前途的新方法，但作为单一疗法，并且在有限的组合中使用，如在凋亡诱导剂/敏化剂组合中发现的那样，它很可能导致靶细胞群的突变逃逸和耐药性的出现。然而，利用越来越多的分子数据作为基础，进行复杂的联合治疗，结合多种关键成分，如细胞死亡诱导剂、激酶抑制剂和 BH3 模拟物，具有很大的潜力。
